Tag: revance therapeutics

All

Revance Reports Q4 and Full Year 2021 Financial Results; Credits Dermal Filler Sales for Growth

The company also announced progress on its DaxibotulinumtoxinA for Injection for glabellar lines and intent to launch the RHA Redensity dermal filler in the second half of 2022.

Revance Resubmits BLA to FDA for DaxibotulinumtoxinA for Injection
Revance Closes on $300M Note Purchase Agreement with Athyrium Capital Management
FDA Accepts Revance Resubmission for Frown Line Treatment
FDA Approves Revance Daxxify for Frown Lines
Studies Show Efficacy of Daxxify to Treat Frown Lines
Revance Publishes 2 Papers on Daxxify Injectable

All

Sorry, No Posts Found

All

Why Dermal Fillers Market Is Hotter Than Ever

The global dermal fillers market is experiencing significant growth due to the introduction of advanced products, innovative non-invasive procedures, increasing demand for male aesthetics, accessibility of cosmetic procedures, and more.

Physician Speaker Series: Illuminating the Future of Skincare
Microneedling Plus Cupping May Aid Skin Rejuvenation
Cleft Lip Caused by Combination of Genes and Environment